ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the feasibility and effectiveness of ctDNA-MRD
based adjuvant furmonertinib therapy in EGFR mutation-positive stage I lung adenocarcinoma
patients after complete surgical resection.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Beijing CSCO-Allist Cancer Research Foundation Guangzhou Burning Rock Medical Examination Institute Co., Ltd. Shanghai Allist Pharmaceutical Technology Co., Ltd.